Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Leases (2019 - 2025)

Historic Current Leases for Editas Medicine (EDIT) over the last 7 years, with Q3 2025 value amounting to $6.1 million.

  • Editas Medicine's Current Leases fell 6286.22% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 6286.22%. This contributed to the annual value of $14.7 million for FY2024, which is 2045.38% up from last year.
  • As of Q3 2025, Editas Medicine's Current Leases stood at $6.1 million, which was down 6286.22% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Current Leases peaked at $18.2 million during Q2 2024, and registered a low of $6.1 million during Q3 2025.
  • Over the past 5 years, Editas Medicine's median Current Leases value was $10.3 million (recorded in 2021), while the average stood at $10.9 million.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 7603.1% in 2024, then plummeted by 6620.11% in 2025.
  • Over the past 5 years, Editas Medicine's Current Leases (Quarter) stood at $10.3 million in 2021, then rose by 7.5% to $11.1 million in 2022, then increased by 9.76% to $12.2 million in 2023, then increased by 20.45% to $14.7 million in 2024, then crashed by 58.45% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $6.1 million for Q2 2025, and $13.2 million during Q1 2025.